New breast cancer drug data a boost for Eli Lilly
Adding its medicine abemaciclib to standard therapy reduces risk of disease progression by 46%; its efficacy is seen as comparable to that of rival drugs from Pfizer, Novartis
Add BT as a preferred sourceDeeperDive is a beta AI feature. Refer to full articles for the facts.
New York
ELI Lilly staked its claim for a slice of sales in a new class of breast cancer drugs on Sunday as clinical data showed adding its medicine abemaciclib to standard therapy reduced the risk of disease progression by 46 per cent.
Experts at the European Society for Medical Oncology (ESMO) congress in Madrid said the experimental drug's efficacy was comparable to that of rival drugs from Pfizer and Novartis already on the market.
Share with us your feedback on BT's products and services
TRENDING NOW
Air India asks Tata, Singapore Airlines for funds after US$2.4 billion loss
Beijing’s calculated silence on the Iran war
China pips the US if Asean is forced to choose, but analysts warn against reading it like a sports result
Richard Eu on how core values, customers keep Singapore’s TCM chain Eu Yan Sang relevant
